please refer attachement

Pat Growth 25pctRevenue DeclineResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.7%Reaction day

₹26.25

prior close

₹26.77

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-3.1%+5.8% vs market

Commodity Chemicals peers, median of 53sector-2.6%+5.3% vs sector

On the reaction day the stock moved 5.8 pts more than Nifty Microcap 250 and 5.3 pts more than its Commodity Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.2

10m

+0.2

15m

+0.2

30m

+0.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.7-3.1+5.8-2.6+5.3

Next day

+2.2-2.4+4.6-2.9+5.1

+2.8-2.2+5.0-1.6+4.5

+1.7-2.5+4.2-2.3+4.0

-2.9-3.8+1.0-3.8+1.0

+0.6-3.4+4.0-3.6+4.1

-3.8-1.8-2.0-2.8-1.0

15d

-1.6+0.1-1.7-4.0+2.4

-1.0+1.2-2.2-3.1+2.1

-2.2+7.9-10.1-5.9+3.7

-10.4+10.3-20.6-3.6-6.8

UpDownMarket · Nifty Microcap 250Sector · Commodity Chemicals peers, median of 53Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Emmessar Biotech reported FY2026 revenue from operations of ₹37.08 lakh, down sharply from ₹61.09 lakh in FY2025 — a ~39% decline in core business revenue. However, total income stood at ₹240.66 lakh (down 8% from ₹261.96 lakh) due to other income of ₹203.58 lakh from rent on leasehold land. Profit after tax grew 37.8% to ₹43.59 lakh from ₹31.62 lakh, with EPS at ₹0.81 vs ₹0.61 prior year. The company operates in two segments: Healthcare (core biotech business declining) and Rent on leasehold land (stable rental income). The auditor issued an unmodified opinion confirming clean books.

Likely market impact

Revenue decline in the core healthcare segment is a concern, but strong PAT growth and positive operating cash flow of ₹26.51 lakh provide some comfort. The stock may face pressure due to the near-40% drop in operational revenue despite the company's ability to maintain profitability through rental income.